March 25, 2011 – A new galectin-3 test, recently cleared by the U.S. Food and Drug Administration (FDA) to help assess the prognosis of patients with chronic heart failure, is now offered by Health Diagnostic Laboratory (HDL). BG Medicine Inc. announced the agreement under which HDL will offer galectin-3 testing services based on the BG Medicine Galectin-3 Test.

March 25, 2011 – The American College of Cardiology (ACC) and the American Heart Association (AHA) have released a focused update to the 2007 guidelines for the managing patients with unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI).

March 25, 2011 – A new, next-generation aspiration catheter has been introduced in the United States. The Fetch 2 Catheter, by Medrad Interventional, features a flexible, variable pitch coiled shaft for improved kink resistance.


During a sudden cardiac arrest (SCA), heart function ceases – abruptly and without warning – most often due to the onset of a ventricular tachyarrhythmia [1]. Because out-of-hospital survival is less than 8 percent, prediction and prevention are critically important [2].

March 24, 2011 – Infinitt North America and Intelligent Business Solutions (IBS) announced a marketing partnership to enable a single point-of-access to both the CardioPulse Cardiovascular Information System (CVIS) and Infinitt Cardiology Picture Archiving and Communications System (PACS) functionality.

March 24, 2011 - The first implant in the United Kingdom of the Omega Platinum Chromium Bare-Metal Coronary Stent System was announced by Boston Scientific. The stent recently received CE mark approval. The first implant was performed by Dr. Neal Uren, consultant cardiologist, Royal Infirmary of Edinburgh.

March 23, 2011 - Millar Instruments Inc. is issuing a worldwide recall of 1,080 units of its Human Use High Injection Angiographic Catheter because they may contain particulate debris within the catheter lumen.

March 22, 2011 – The U.S. Food and Drug Administration (FDA) has approved a 210-patient investigation devices exemption (IDE) clinical trial to test the efficacy of a bone marrow stem cell technology to treat patients with non-reconstructable critical limb ischemia (CLI).

The U.S. Food and Drug Administration (FDA) has granted InfiMed 510(k) market clearance for its i5 Nexus-DRF multi-purpose digital imaging system. The new i5 product line combines radiographic fluoroscopy (RF), digital radiography (DR) and cardiac capabilities on one imaging platform using various industry-leading flat panel detectors.

March 23, 2011 –The fifth in a series of in-depth market studies dedicated to the compact ultrasound market indicates that this segment outpaced the overall ultrasound market in 2010, reaching $276 million in the United States, a 21 percent increase from the prior year.

Subscribe to
Β© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now